ValuEngine Downgrades Spring Bank Pharmaceuticals (SBPH) to Sell

Spring Bank Pharmaceuticals (NASDAQ:SBPH) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

SBPH has been the topic of several other reports. B. Riley assumed coverage on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective on the stock. Chardan Capital reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Sunday, September 17th. Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Finally, Cantor Fitzgerald set a $29.00 price objective on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $27.25.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) opened at $13.98 on Friday. Spring Bank Pharmaceuticals has a 12 month low of $6.31 and a 12 month high of $18.93.

A number of institutional investors and hedge funds have recently made changes to their positions in SBPH. DAFNA Capital Management LLC acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at $217,000. C WorldWide Group Holding A S acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at $340,000. EAM Investors LLC acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at $578,000. Vanguard Group Inc. acquired a new position in Spring Bank Pharmaceuticals in the 2nd quarter valued at $794,000. Finally, Morse Asset Management Inc boosted its position in shares of Spring Bank Pharmaceuticals by 156.9% during the 2nd quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after purchasing an additional 38,900 shares in the last quarter. 29.70% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “ValuEngine Downgrades Spring Bank Pharmaceuticals (SBPH) to Sell” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/03/valuengine-downgrades-spring-bank-pharmaceuticals-sbph-to-sell.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

What are top analysts saying about Spring Bank Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spring Bank Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit